Brief: Astellas Says Padcev+Keytruda Cuts Risk Of Recurrence/Death By Nearly 50% In Patients With Bladder Cancer
27/02/2026 15:32
Feb 27 (Reuters) - Astellas Pharma Inc 4503.T: PADCEV™ + KEYTRUDA® CUTS RISK OF RECURRENCE OR DEATH BY NEARLY 50% IN CISPLATIN-ELIGIBLE MUSCLE-INVASIVE BLADDER CANCER ASTELLAS- SAFETY PROFILE FOR PERIOPERATIVE ENFORTUMAB VEDOTIN PLUS PEMBROLIZUMAB OBSERVED IN EV-304 CONSISTENT WITH PRIOR EXPERIENCE WITH COMBINATION Source text: ID:nBw7lsksZa Further company coverage: 4503.T ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Astellas Pharma
See all newsFocus: Trump's push for the world's lowest drug prices hits snag with mid-sized companies
China detains two Japanese nationals suspected of smuggling banned goods (updated)
Brief: Astellas Pharma: Institutional Shareholder Services Has Issued A Report Recommending A Vote Against A Director Candidate
Health Rounds: Veracyte genomic test identifies breast cancer patients who can skip chemo
Advisory: Alert wrongly tagged to Gold Rain Enterprises withdrawn